PubMed Health⌕ Search

Biomedical subjects

K C Yeh

Publications and source records attributed to K C Yeh.

15 recordsLinked to original sources
PubMed1991

Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR).

The gastrointestinal transit and systemic absorption of Sinemet CR (50-200) controlled-release tablets and standard Sinemet (25-100) immediate-release (IR) tablets have been studied in fasted and fed healthy human subjects. Both formulations were labelled with a gamma-emitting radionuclide and their gastric emptying, colon arrival and in vivo disintegration profiles monitored using gamma scintigraphy. The IR dosage forms were found to disperse soon after administration and to empty rapidly from both fasted and fed stomachs. Erosion of the CR system was independent of food or stomach pH. The CR tablet was observed to disintegrate fully in the gastrointestinal (GI) tract, resulting in complete release of levodopa over a 3-4 h time period. Considerable intersubject variation was found to exist for levodopa absorption. Absorption was more protracted with Sinemet CR than with standard Sinemet, due to the controlled release characteristics of the tablet matrix. There was no rapid initial absorption phase and instead, a gradual build-up in the absorption profile occurred.

Adult↗
PubMed1990

Simultaneous high-performance liquid chromatographic analysis of carbidopa, levodopa and 3-O-methyldopa in plasma and carbidopa, levodopa and dopamine in urine using electrochemical detection.

Two assay procedures are described for the analysis of levodopa, carbidopa and 3-O-methyldopa in plasma and levodopa, carbidopa and dopamine in urine. The methods are suitable for quantifying the analytes following therapeutic administration of levodopa and carbidopa. Both were based on reversed-phase high-performance liquid chromatography (HPLC) with electrochemical detection and with methyldopa as the internal standard. Plasma samples were prepared by perchloric acid precipitation followed by the direct injection of the supernatant. Urine was prepared by alumina adsorption, and the analytes were desorbed with perchloric acid solution containing disodium EDTA and sodium metabisulfite prior to injection into the HPLC system. The methods have been utilized to evaluate the pharmacokinetics and bioavailability of oral dosage forms containing levodopa and carbidopa.

Carbidopa↗
PubMed1990

Inhibition of human periodontal prostaglandin E2 synthesis with selected agents.

Considerable evidence has demonstrated the importance of PGE2 synthesis in the pathogenesis of periodontal disease. Although various cyclooxygenase inhibitors have been known to block periodontal PGE2 synthesis and prevent disease progression in animal models, there are few reports comparing relative efficacies of various inhibitors of arachidonic acid (ARA) metabolism. We have developed a sensitive in vitro assay to measure PGE2 synthesis in periodontal tissues. The apparent IC50 values (i.e. the concentration of drug which causes 50% inhibition of maximum PGE2 synthesis) have been determined for a series of arachidonic acid analogues as well as competitive and non-competitive cyclooxygenase inhibitors. Periodontal tissue homogenates were incubated in the presence of 3H-arachidonic acid for 45 min at 37 degrees C. Inhibitors were tested at 10(-10)-10(-4) M and at zero concentration to measure conversion of 3H-arachidonate to 3H-PGE2. Log or half log dilutions of inhibitors were tested in triplicate for each assay. Radiolabeled PGE2 was extracted from homogenates, purified by reverse phase chromatography and quantitated by double antibody capture. RIA was performed on each homogenate to determine the amount of endogenous unlabeled PGE2 present in the sample to correct for antibody capture recovery. The apparent IC50 values were determined for each drug by averaging two or more replicate assays. Specific total enzymatic activity of periodontal tissue homogenates was typically 5-11 pg PGE2/min/mg tissue.(ABSTRACT TRUNCATED AT 250 WORDS)

Arachidonic Acid↗
PubMed1979

Kinetic parameter estimation by numerical algorithms and multiple linear regression: application to pharmacokinetics.

Two numerical examples are presented to illustrate the application of the proposed method of parameter estimation in pharmacokinetics. Results for a system exemplifying first-order kinetics indicate that parameters estimated by the proposed procedure compare favorably with those estimated by a nonlinear regression method. In a simulated example characterized by Michaelis-Menten elimination kinetics, the accuracy of the estimated parameters was comparable to that expected, verifying the validity of the method. The importance of the numerical approximation algorithms was demonstrated also.

Kinetics↗
PubMed1977

Kinetic parameter estimation by numerical algorithms and multiple linear regression: theoretical.

A new method is presented for the determination of kinetic parameters based on a functional relationship among experimental data derived from the postulated model. The data, even though containing errors, are manifestations of this relationship, which should be satisfied by parameters fitted to the system. The procedure involves the use of numerical integration and/or differentiation of the data, followed by multiple linear regression. It does not require initial estimates or repetitive iteration for linear systems and can be applied to nonlinear models. The accuracy of estimated parameter depends on the goodness of the particular numerical approximation method used.

Computers↗
PubMed1976

Oil-water distribution of p-alkylpyridines.

The distribution of a homologous series of p-alkylpyridines between water and six organic solvents with varying degrees of polarity was investigated. The distribution coefficients were considered as reflections of the strength of net interactions involved in the solvents. The order was chloroform greater than octanol greater than carbon tetrachloride greater than butyl ether greater than hexadecane greater than octane. The effect of the methylene group upon the distribution coefficients differed little among the six solvents. The relative constancy was attributed to the predominance of the dispersion forces in the incremental effect.

Hydrogen-Ion Concentration↗
PubMed1976

Bioavailability assessment under quasi- and nonsteady-state conditions II: study designs.

The flexibility of bioavailability assessment at quasi-and nonsteady state is demonstrated by systematically removing experimental constraints from the study design. Mathematical expressions are derived to describe each design variation. From the resultant solutions, it is evident that the proposed method can accommodate nonuniformities in dose, dosage interval, dosage regimen, dosing cycle, sampling interval, plasma half-life, washout period, and protocol adherence. Nominal requirements for the method are linear kinetics and mean plasma concentrations estimated over time intervals beginning and ending in the log-linear region.

Biological Availability↗
PubMed1976

Interpretation of distribution coefficients of p-alkylpyridines by a modified regular solution theory.

The hypothetical hexadecane-octane distribution coefficients for the alkylpyridines were deduced from the corresponding oil-water distribution data. The values were analyzed by a modified regular solution theory. A good correlation was noted by including the Flory-Huggins entropy factor in the calculation and by considering the deviation from the geometric mean assumption.

Chemical Phenomena↗
PubMed1976

Bioavailability assessment under quasi- and nonsteady-state conditions III: Application.

The applicability of bioavailability assessment at quasi- and nonsteady state is illustrated with data from a study comparing two formulations of amitriptyline hydrochloride in humans. Relative bioavailability as a function of the observed mean plasma concentrations may be expressed in closed form, provided the affected intervals begin and end in the log-linear region. Alternatively, numerical, graphical and/or electronic computational techniques may be used to stimulate the appropriate [Cp(i)]sim, the proximity of which to [Cp(i)]obs is a function of relative bioavailability and omega. If a model can be found to fit the data adequately, it would be sufficient that only one sampled interval end in the log-linear phase.

Amitriptyline↗
PubMed1975

Bioavailability of oral dexamethasone.

Bioavailabilities of dexamethasone tablets and elixir in man were evaluated by each of 3 model-independent methods of pharmacokinetic analysis employing plasma and urinary values as determined by radioimmune assay. There were no significant differences among the results determined by the 3 methods nor between the respective availabilities of the two formulations; the latter averaged 82.6 +/- 17.7% for the elixir formulation and 78.0 +/- 12.1% for tablets.

Administration, Oral↗
PubMed1975

Bioavailability of dexamethasone. II. Dexamethasone phosphate.

Plasma levels of dexamethasone phosphate (DP) and dexamethasone free alcohol (DA) were determined by a modification of existing radioimmunoassay methodology following intravenous administration of DP in man. Areas under DA plasma profiles were a linear function of DP dosage over the 40-fold range 0.05 to 2.0 mg/kg, and, by comparison with values obtained after DA was intravenously administered, indicated an overall conversion of DP to DA of 90%. The first-order rate constant for the conversion, 4.03 hr-1, was approximately 25 times that for hydrolysis in whole blood incubated in vitro. This relationship as well as disposition kinetics suggested that the major component of DP hydrolysis occurs within highly perfused organ(s) comprising the central kinetic compartment. Eighteen subjects were studied in a crossover experiment, and no significant differences were observed in best-fit parameters for the 4 mg/ml parenteral solution of DP in current use and an experimental high potency preparation of 24 mg/ml.

Adolescent↗
PubMed1975

Bioavailability assessment under quasi- and nonsteady-state conditions. I: theoretical considerations.

A strategy was devised to permit bioavailability estimations at quasi- and nonsteady states. The proposed method retains most attributes of a steady-state comparison without being burdened by its protractiveness. The only necessary requirements are that drug disposition obeys linear kinetics and that succeeding doses are administered during the log-linear phase free from the influence of continuing absorption.

Biological Availability↗
PubMedDate not supplied

Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins.

Features of the distribution, metabolism, elimination, and pharmacokinetics of the cephalosporins and cefoxitin must be considered when concentrations of these drugs in biological fluids are interpreted. The extensive (approximately 86%) binding of cefazolin to plasma protein may account for the smaller volume of distribution and slower rate of renal clearance than are observed for cefoxitin, which is less extensively (73%) bound to protein. Results of microbiological assays of drug in urine may be influenced by the extent of metabolism of the drugs, which is 33% for cephalothin but less than 2% for cefoxitin. Elimination of cephalosporins and cefoxitin occurs by both glomerular filtration and tubular secretion and can be inhibited by the concurrent administration of probenecid. The pharmacokinetics of cefoxitin may be described by a linear, two-compartment, open model that has been used to predict levels of drug achieved in serum and urine after various dose regimens, including administration by intravenous bolus or infusion. The bioavailability of intramuscularly administered cefoxitin is equivalent to that of intravenously administered cefoxitin and is 90% complete within 3-4 hr after the dose is given.

Biological Availability↗